Baris Akinci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6527542/publications.pdf

Version: 2024-02-01

257429 361001 1,719 96 24 35 h-index citations g-index papers 97 97 97 2323 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options. Updates in Surgery, 2022, 74, 325-335.	2.0	10
2	Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes. BMC Medicine, 2022, 20, 95.	5.5	6
3	The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe Obesity. Obesity, 2021, 29, 274-278.	3.0	6
4	Cardiac phenotype in familial partial lipodystrophy. Clinical Endocrinology, 2021, 94, 1043-1053.	2.4	7
5	Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2953-e2967.	3.6	13
6	The Long-Term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy. Journal of the Endocrine Society, 2021, 5, A29-A30.	0.2	0
7	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med, 2021, 2, 814-835.e6.	4.4	12
8	Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy. BMJ Open Diabetes Research and Care, 2021, 9, e002385.	2.8	0
9	Complications of lipodystrophy syndromes. Presse Medicale, 2021, 50, 104085.	1.9	3
10	Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids in Health and Disease, 2021, 20, 174.	3.0	11
11	Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy. Clinical Diabetes and Endocrinology, 2020, 6, 13.	2.7	2
12	Diabetic Foot Ulcers: A Neglected Complication of Lipodystrophy. Diabetes Care, 2020, 43, e149-e151.	8.6	4
13	Diagnostic strategies and clinical management of lipodystrophy. Expert Review of Endocrinology and Metabolism, 2020, 15, 95-114.	2.4	20
14	Unusual Presentations of LMNA-Associated Lipodystrophy with Complex Phenotypes and Generalized Fat Loss: When the Genetic Diagnosis Uncovers Novel Features. AACE Clinical Case Reports, 2020, 6, e79-e85.	1.1	9
15	European lipodystrophy registry: background and structure. Orphanet Journal of Rare Diseases, 2020, 15, 17.	2.7	21
16	The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.5	5
17	The Role of Adiponectin in Maintaining Metabolic Homeostasis. Current Diabetes Reviews, 2020, 16, 95-103.	1.3	19
18	Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2020, 12, 17-28.	0.9	16

#	Article	IF	CITATIONS
19	Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, 2020, 31, 588-595.	1.1	0
20	Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, 2020, 31, 588-595.	1.1	2
21	Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors. Modern Rheumatology, 2019, 29, 619-624.	1.8	22
22	Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5120-5135.	3.6	29
23	THU0690â€DISEASE ACTIVITY CORRELATES WITH INSULIN RESISTANCE AND ADIPOCYTOKINES IN PATIENTS WIDMARD-NAÃVE RHEUMATOID ARTHRITISÂ. , 2019, , .	тн	0
24	A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities. Endocrine Research, 2019, 44, 46-54.	1.2	9
25	Tip 2 Diabetes Mellitus Hastalarında Statin Kullanımı ve Hedefe Ulaşma Oranları: Direnç Hastada mı Hekimde mi?. Turkish Journal of Diabetes and Obesity, 2019, 3, 65-72.	0.3	0
26	Renal complications of lipodystrophy: A closer look at the natural history of kidney disease. Clinical Endocrinology, 2018, 89, 65-75.	2.4	16
27	Airway and sleep disorders in patients with acromegaly. Clinical Respiratory Journal, 2018, 12, 1003-1010.	1.6	17
28	Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. Current Diabetes Reports, 2018, 18, 143.	4.2	53
29	"Fat Shadows―From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. Diabetes Care, 2018, 41, 2255-2258.	8.6	18
30	Update on Therapeutic Options in Lipodystrophy. Current Diabetes Reports, 2018, 18, 139.	4.2	25
31	Does the ACR TI-RADS scoring allow us to safely avoid unnecessary thyroid biopsy? single center analysis in a large cohort. Endocrine, 2018, 61, 398-402.	2.3	20
32	A new type of familial partial lipodystrophy: distinctive fat distribution and proteinuria. Endocrine Research, 2018, 43, 258-263.	1.2	1
33	Cytologic Comparison Between Growing and Non-growing Benign Thyroid Nodules Evaluated Using Two Different Growth Criteria. Turkish Journal of Endocrinology and Metabolism, 2018, 22, 16-20.	0.5	1
34	Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide. Journal of Physical Education and Sports Management, 2017, 3, a001339.	1.2	9
35	The Effect of Retraining on Treatment Success, Quality of Life, and Metabolic Parameters in Patients with Type 1 Diabetes Using an Insulin Pump. Medical Principles and Practice, 2017, 26, 325-330.	2.4	4
36	Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metabolism: Clinical and Experimental, 2017, 72, 109-119.	3.4	54

#	Article	IF	CITATIONS
37	First metreleptin treatment for generalized lipodystrophy in Turkey. Diabetes, Obesity and Metabolism, 2017, 19, 299-301.	4.4	4
38	Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy. Diagnostic and Interventional Radiology, 2017, 23, 428-434.	1.5	22
39	Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscular Disorders, 2017, 27, 923-930.	0.6	20
40	Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor â€Ĵ³ (<i><scp>PPARG</scp></i>) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (<i><scp>LMNA</scp></i>) mutations. Diabetic Medicine, 2016, 33, 1445-1450.	2.3	18
41	Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. European Journal of Medical Genetics, 2016, 59, 320-324.	1.3	23
42	Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2759-2767.	3.6	67
43	A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N). European Journal of Internal Medicine, 2016, 29, 37-39.	2.2	6
44	Partial lipodystrophy of the limbs in a diabetes clinic setting. Primary Care Diabetes, 2016, 10, 293-299.	1.8	2
45	Endothelium-Dependent Hemostatic Factors in Women with Previous Gestational. Turkish Journal of Endocrinology and Metabolism, 2016, 20, 43-47.	0.5	1
46	Mean Platelet Volume in Women with Gestational Diabetes. Turkish Journal of Endocrinology and Metabolism, 2016, 20, 48-53.	0.5	4
47	SPG11 mutation in a Turkish familial hypobetalipoproteinemia family with hereditary spastic paraplegia. Clinica Chimica Acta, 2015, 445, 1.	1.1	0
48	Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism: Clinical and Experimental, 2015, 64, 1086-1095.	3.4	25
49	Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2015, 9, 74-78.	0.6	6
50	Circulating apelin levels are associated with cardiometabolic risk factors in women with previous gestational diabetes. Archives of Gynecology and Obstetrics, 2014, 289, 787-793.	1.7	24
51	Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid. Journal of Diabetes and Its Complications, 2014, 28, 844-849.	2.3	5
52	Postload hyperglycemia is associated with increased subclinical inflammation in patients with prediabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 422-427.	1.2	14
53	Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 210-217.	0.6	7
54	Insulin Need in Gestational Diabetes is Associated with a Worse Cardiovascular Risk Profile after Pregnancy. Internal Medicine, 2012, 51, 839-843.	0.7	8

#	Article	IF	CITATIONS
55	A Puzzling Case of Phospho-Soda-induced Hypocalcemia in a Patient with Multiple Endocrine Neoplasia Type 1-associated Primary Hyperparathyroidism. Internal Medicine, 2012, 51, 3145-3149.	0.7	1
56	Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskeletal Disorders, 2012, 13, 191.	1.9	77
57	Evaluation of postpartum carbohydrate intolerance and cardiovascular risk factors in women with gestational diabetes. Gynecological Endocrinology, 2011, 27, 361-367.	1.7	40
58	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels Are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E224-E230.	1.7	2
59	Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. Diabetes Research and Clinical Practice, 2011, 91, 26-31.	2.8	33
60	The Alteration of Coagulation in Patients with Thyroid Dysfunction. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2011, 5, 50-57.	0.6	5
61	Effect of Levothyroxine Suppression Therapy on Plasma Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels in Benign Thyroid Nodules. Medical Principles and Practice, 2011, 20, 23-28.	2.4	8
62	Acute Phase Reactants Predict the Risk of Amputation in Diabetic Foot Infection. Journal of the American Podiatric Medical Association, 2011, 101, 1-6.	0.3	30
63	Allergic reactions to human insulin: a review of current knowledge and treatment options. Endocrine, 2010, 37, 33-39.	2.3	35
64	Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine, 2010, 37, 40-46.	2.3	85
65	The effect of creatinine clearance on the short-term outcome of neuropathic diabetic foot ulcers. Primary Care Diabetes, 2010, 4, 181-185.	1.8	4
66	Management of gestational diabetes by physicians in Turkey. Primary Care Diabetes, 2010, 4, 173-180.	1.8	5
67	Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. Journal of Endocrinological Investigation, 2010, 33, 32-36.	3.3	32
68	Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertility and Sterility, 2010, 93, 1248-1254.	1.0	48
69	Beneficial Effect of Endocrinologist-Performed Ultrasonography on Preoperative Parathyroid Adenoma Localization. Endocrine Practice, 2009, 15, 17-23.	2.1	13
70	Predictors of amputation in diabetics with foot ulcer: Single center experience in a large Turkish cohort. Hormones, 2009, 8, 286-295.	1.9	85
71	Soluble CD40 Ligand, Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fibrinolysis Inhibitor-1-Antigen in Normotensive Type 2 Diabetic Subjects without Diabetic Complications. Medical Principles and Practice, 2009, 18, 266-271.	2.4	17
72	Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine, 2009, 35, 365-370.	2.3	39

#	Article	IF	CITATIONS
73	Natural course of benign adrenal incidentalomas in subjects with extra-adrenal malignancy. Endocrine, 2009, 36, 135-140.	2.3	6
74	Levothyroxine (LT ₄) suppression treatment for benign thyroid nodules alters coagulation. Clinical Endocrinology, 2009, 71, 446-450.	2.4	16
75	Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clinical Cardiology, 2009, 32, 32-36.	1.8	18
76	Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. Clinical Rheumatology, 2008, 27, 859-865.	2.2	36
77	Severe hypocalcaemia because of osteoblastic prostate carcinoma metastases. International Journal of Clinical Practice, 2008, 62, 1630-1631.	1.7	8
78	Hashimoto's Thyroiditis, but not Treatment of Hypothyroidism, Is Associated with Altered TGF-Î ² 1 Levels. Archives of Medical Research, 2008, 39, 397-401.	3.3	29
79	Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia. Clinica Chimica Acta, 2008, 390, 152-155.	1.1	5
80	Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy. Diabetes Research and Clinical Practice, 2008, 81, 93-96.	2.8	14
81	Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Research and Clinical Practice, 2008, 82, 172-178.	2.8	44
82	Is fasting glucose level during oral glucose tolerance test an indicator of the insulin need in gestational diabetes?. Diabetes Research and Clinical Practice, 2008, 82, 219-225.	2.8	41
83	Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2008, 2, 57-61.	0.6	0
84	Management of Hyperglycemia in Gestational Diabetes Mellitus. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2008, 2, 123-128.	0.6	0
85	Evaluation of markers of inflammation, insulin resistance and endothelial dysfunction in children at risk for overweight. Hormones, 2008, 7, 156-162.	1.9	30
86	Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones, 2008, 7, 70-76.	1.9	16
87	Alterations of coagulation in metformin intoxication. Hormones, 2008, 7, 325-329.	1.9	16
88	Plasma Thiobarbituric Acid-Reactive Substance Levels in Subclinical Hypothyroidism. Medical Principles and Practice, 2007, 16, 432-436.	2.4	26
89	Elevated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels in Overt and Subclinical Hypothyroid Patients Were Reduced by Levothyroxine Replacement. Endocrine Journal, 2007, 54, 45-52.	1.6	40
90	Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels Are Inversely Correlated with Plasminogen Activator Inhibitor-1 Antigen Levels in Hyperthyroid Patients. Endocrine Journal, 2007, 54, 593-599.	1.6	21

#	Article	IF	CITATION
91	Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus. Diabetes Research and Clinical Practice, 2007, 76, 193-198.	2.8	24
92	Atherosclerosis risk factors in children of parents with the metabolic syndrome. Atherosclerosis, 2007, 194, e165-e171.	0.8	11
93	The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey. Leukemia and Lymphoma, 2007, 48, 1372-1378.	1.3	10
94	Amelanotic melanoma misdiagnosed as a diabetic foot ulcer. Journal of Diabetes and Its Complications, 2007, 21, 335-337.	2.3	12
95	Mesalazine-induced myopericarditis in a patient with ulcerative colitis. International Journal of Colorectal Disease, 2006, 21, 199-200.	2.2	23
96	A case of familial Mediterranean fever and polyarteritis nodosa complicated by spontaneous perirenal and subcapsular hepatic hemorrhage requiring multiple arterial embolizations. Rheumatology International, 2005, 25, 60-64.	3.0	14